Disease Markers

Research Article

The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder

Table 3

Pre- and posttreatment VDSS and bladder volumes according to ARGEF10, ADRB3, ROCK, and CYP3A4 allelic types.
Gene allelePretreatment VDSS mean ± SDPosttreatment VDSS mean ± SDPretreatment bladder volume (mL) mean ± SDPosttreatment bladder volume (mL) mean ± SD
ARGEF10      
 CC7,72 ± 9,262,50 ± 5,25<0,001183,50 ± 63,92312,86 ± 122,75<0,001
 CG6,67 ± 10,802,44 ± 5,930,026178,29 ± 156,13260,43 ± 141,970,030
 GG9,33 ± 10,071,67 ± 2,890,343125 ± 35,36275 ± 106,070,205
ADRB3      
 TT7,83 ± 9,472,41 ± 5,22<0,001179,25 ± 89,08308,84 ± 130,58<0,001
 TC5,82 ± 10,332,73 ± 6,070,111180 ± 67,45250 ± 55,230,199
ROCK      
 AC6,76 ± 9,821,83 ± 4,860,001211,23 ± 121,29304,15 ± 154,680,020
 AA8,11 ± 8,642,57 ± 4,940,001178,20 ± 57,98325,57 ± 116,36<0,001
 CC7,89 ± 10,93,28 ± 6,590,016135,22 ± 35,11255,56 ± 80,330,001
CYP3A4      
 AA7,78 ± 9,522,52 ± 5,34<0,001172,97 ± 83,53295,41 ± 126,85<0,001
 AG5,5 ± 10,311,88 ± 5,300,280251,67 ± 91,88363 ± 78,080,075